Back to AVEOView full pipeline
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
0 competitors in Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
View Full LandscapeDrug Information
Target Indication
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Clinical Trial
NCT03013998Last updated: 10/21/2026
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Drug Science
Mechanism of action & safety profile
Related Pipeline
tivozanib (AV-951)Phase 3
Advanced Renal Cell Carcinoma
TivozanibPhase 3
Renal Cell Carcinoma
Tivozanib hydrochloridePhase 3
Carcinoma, Renal Cell
FiclatuzumabPhase 3
Metastatic Head-and-neck Squamous-cell Carcinoma
AZD5991 (BAML-16-001-S18)Phase 3
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
